Brain and Spinal Tumors: Our Approach and Expertise

The Division of Neuro-Oncology at Herbert Irving Comprehensive Cancer Center provides comprehensive, state-of-the-art diagnosis and treatment of patients with brain and spinal tumors.  This integrated division draws on the expertise of world-class institutions at NewYork-Presbyterian/Columbia University Medical Center and Weill Cornell Medical Center, including:

  • The Department of Neurology at Columbia University. Known for its exceptional patient care, research, and education programs, this department is in the top five in the nation for NIH-funded research on neurologic diseases.
  • The Neurological Institute of NewYork-Presbyterian/Columbia University Medical Center. The Neurological Institute was the first center in the nation to be established for the study and treatment of neural diseases. 
  • The Neuro-Oncology Division and integrated Brain Tumor Center at Columbia University. Established in 2005, this center applies the research performed at the Neurological Institute to the treatment of patients with malignant brain tumors.
  • The Department of Neurosurgery at Columbia University Medical Center, recognized as one of the top five programs in the nation for the surgical treatment of brain and spinal tumors.
  • Brain Tumor Centers at NewYork-Presbyterian/Weill Cornell Medical Center. Together with its counterpart center at Columbia University Medical Center, the Brain Tumor Centers are at the forefront of brain tumor research, and are among the busiest treatment centers in the nation.
  • Weill Cornell Brain and Spine Center. The Brain and Spine center provides the most advanced care for the full spectrum of neurologic conditions.

The Herbert Irving Comprehensive Cancer Center stands at the forefront of brain tumor research. The center’s clinical activities are combined with vigorous research efforts aimed at improving outcomes for patients with brain and spinal tumors. Clinicians and laboratory investigators at HICCC collaborate to better understand the growth and development of brain and spinal tumors and to ultimately develop new treatments. Patients with primary tumors, as well as those with metastatic disease (cancer that spreads to the brain or spine from other sites), have access to a wide range of clinical trials, including single and large multicenter studies assessing new anticancer agents and novel ways of administering therapy.